We hope you will join us for the 2023 Herman P. Schwan Distinguished Lecture by Dr. Dorin Comaniciu, hosted by the Department of Bioengineering.
Wednesday, December 13, 2023 1:00 PM ET Location: Wu & Chen Auditorium (Levine 101) The lecture and Q&A will be followed by a light reception in Levine Lobby.
Speaker:Dorin Comaniciu, Ph.D. Senior Vice President Artificial Intelligence and Digital Innovations Siemens Healthineers
About Dorin Comaniciu:
Dr. Comaniciu serves as Senior Vice President for Artificial Intelligence and Digital Innovation at Siemens Healthineers. His scientific contributions to machine intelligence and computational imaging have translated to multiple clinical products focused on improving the quality of care, specifically in the fields of diagnostic imaging, image-guided therapy, and precision medicine.
Comaniciu is a member of the National Academy of Medicine, the Romanian Academy, and a Top Innovator of Siemens. He is a Fellow of the IEEE, ACM, MICCAI Society, and AIMBE, and a recipient of the IEEE Longuet-Higgins Prize for fundamental contributions to computer vision. Recent recognition of his work includes an honorary doctorate from Friedrich-Alexander University of Erlangen-Nuremberg.
He has co-authored 550 granted patents and 350 peer-reviewed publications that have received 61,000 citations, with an h-index of 102, in the areas of machine intelligence, medical imaging, and precision medicine.
A graduate of University of Pennsylvania’s Wharton School, Comaniciu received a doctorate in electrical and computer engineering from Rutgers University and a doctorate in electronics and telecommunications from Polytechnic University of Bucharest.
He is an advocate for technological innovations that save and enhance lives, addressing critical issues in global health.
About the Schwan Lecture:
The Herman P. Schwan Distinguished Lecture is in honor of one of the founding members of the Department of Bioengineering, who emigrated from Germany after World War II and helped create the field of bioengineering in the US. It recognizes people with a similar transformative impact on the field of bioengineering.
Vaccines for COVID-19 were the first time that mRNA technology was used to address a worldwide health challenge. The Penn Medicine scientists behind that technology were awarded the 2023 Nobel Prize in Physiology or Medicine. Next come all the rest of the potential new treatments made possible by their discoveries.
But curbing the pandemic was only the beginning of the potential for this Nobel Prize-winning technology.
These biomedical innovations from Penn Medicine in using mRNA represent a multi-use tool, not just a treatment for a single disease. The technology’s potential is virtually unlimited; if researchers know the sequence of a particular protein they want to create or replace, it should be possible to target a specific disease. Through the Penn Institute for RNA Innovation led by Weissman, who is the Roberts Family Professor of Vaccine Research in Penn’s Perelman School of Medicine, researchers are working to ensure this limitless potential meets the world’s most challenging and important needs.
Infectious Diseases and Beyond
Just consider some of the many projects Weissman’s lab is partnering in: “We’re working on malaria with people across the U.S. and in Africa,” Weissman said. “We’re working on leptospirosis with people in Southeast Asia. We’re working on vaccines for peanut allergies. We’re working on vaccines for autoimmunity. And all of this is through collaboration.”
Clinical trials are underway for the new malaria vaccine, as well as for a Penn-developed mRNA vaccine for genital herpes and one that aims to protect against all varieties of coronaviruses. Trials should begin soon for vaccines for norovirus and the bacterium C. difficile.
Single-Injection Gene Therapies for Sickle Cell and Heart Disease
Drew Weissman, MD, PhD, is a co-winner of the 2023 Nobel Prize in Physiology or Medicine for discoveries with mRNA.
The Weissman lab is working to deploy mRNA technology as an accessible gene therapy for sickle cell anemia, a devastating and painful genetic disease that affects about 20 million people around the world. About 300,000 babies are born each year with the condition, mainly in sub-Saharan Africa. Weissman’s team has developed technology to efficiently deliver modified mRNA to bone marrow stem cells, instructing red blood cells to produce normal hemoglobin instead of the malformed “sickle” version that causes the illness. Conventional gene therapies are complex and expensive treatments, but the mRNA gene therapy could be a simple, one-time intravenous injection to cure the disease. Such a treatment would have applications to many other congenital gene defects in blood and stem cells.
In another new program, Penn Medicine researchers have found a way to target the muscle cells of the heart. This gene therapy method developed by Weissman’s team, together with Vlad Muzykantov, MD, PhD, the Founders Professor in Nanoparticle Research could potentially repair the heart or increase blood flow to the heart, noninvasively, after a heart attack or to correct a genetic deficiency in the heart. “That is important because heart disease is the number one killer in the U.S. and in the world,” Weissman said. “Drugs for heart disease aren’t specific for the heart. And when you’re trying to treat a myocardial infarction or cardiomyopathy or other genetic deficiencies in the heart, it’s very difficult, because you can’t deliver to the heart.”
Weissman’s team also is partnering on programs for neurodevelopmental diseases and for neurodegenerative diseases, to replace genes or deliver therapeutic proteins that will treat and potentially cure these diseases.
“The potential is unbelievable,” Weissman said. “We haven’t thought of everything that can be done.”
Vladimir R. Muzykantov is Founders Professor in Nanoparticle Research in the Department of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine. He is a member of the Penn Bioengineering Graduate Group.
Daeyeon Lee (left), Oren Friedman (center) and Sergei Vinogradov (right)
Each year, the Nemirovsky Engineering and Medicine Opportunity (NEMO) Prize, funded by Penn Health-Tech, awards $80,000 to a collaborative team of researchers from the University of Pennsylvania’s Perelman School of Medicine and the School of Engineering and Applied Science for early-stage, interdisciplinary ideas.
This year, the NEMO Prize has been awarded to Penn Engineering’s Daeyeon Lee, Russel Pearce and Elizabeth Crimian Heuer Professor in Chemical and Biomolecular Engineering, Oren Friedman, Associate Professor of Clinical Otorhinolaryngology in the Perelman School of Medicine, and Sergei Vinogradov, Professor in the Department of Biochemistry and Biophysics in the Perelman School of Medicine and the Department of Chemistry in the School of Arts & Sciences. Together, they are developing a new therapy that improves the survival and success of soft-tissue grafts used in reconstructive surgery.
More than one million people receive soft-tissue reconstructive surgery for reasons such as tissue trauma, cancer or birth defects. Autologous tissue transplants are those where cells and tissue such as fat, skin or cartilage are moved from one part of a patient’s body to another. As the tissue comes from the patient, there is little risk of transplant rejection. However, nearly one in four autologous transplants fail due to tissue hypoxia, or lack of oxygen. When transplants fail the only corrective option is more surgery. Many techniques have been proposed and even carried out to help oxygenate soft tissue before it is transplanted to avoid failures, but current solutions are time consuming and expensive. Some even have negative side effects. A new therapy to help oxygenate tissue quickly, safely and cost-effectively would not only increase successful outcomes of reconstructive surgery, but could be widely applied to other medical challenges.
The therapy proposed by this year’s NEMO Prize recipients is a conglomerate or polymer of microparticles that can encapsulate oxygen and disperse it in sustainable and controlled doses to specific locations over periods of time up to 72 hours. This gradual release of oxygen into the tissue from the time it is transplanted to the time it functionally reconnects to the body’s vascular system is essential to keeping the tissue alive.
“The microparticle design consists of an oxygenated core encapsulated in a polymer shell that enables the sustained release of oxygen from the particle,” says Lee. “The polymer composition and thickness can be controlled to optimize the release rate, making it adaptable to the needs of the hypoxic tissue.”
These life-saving particles are designed to be integrated into the tissue before transplantation. However, because they exist on the microscale, they can also be applied as a topical cream or injected into tissue after transplantation.
“Because the microparticles are applied directly into tissues topically or by interstitial injection (rather than being administered intravenously), they surpass the need for vascular channels to reach the hypoxic tissue,” says Friedman. “Their micron-scale size combined with their interstitial administration, minimizes the probability of diffusion away from the injury site or uptake into the circulatory system. The polymers we plan to use are FDA approved for sustained-release drug delivery, biocompatible and biodegrade within weeks in the body, presenting minimal risk of side effects.”
The research team is currently testing their technology in fat cells. Fat is an ideal first application because it is minimally invasive as an injectable filler, making it versatile in remodeling scars and healing injury sites. It is also the soft tissue type most prone to hypoxia during transplant surgeries, increasing the urgency for oxygenation therapy in this particular tissue type.
The Heilmeier Award honors a Penn Engineering faculty member whose work is scientifically meritorious and has high technological impact and visibility. It is named for the late George H. Heilmeier, a Penn Engineering alumnus and member of the School’s Board of Advisors, whose technological contributions include the development of liquid crystal displays and whose honors include the National Medal of Science and Kyoto Prize.
Raj, who also holds an appointment in Genetics in the Perelman School of Medicine, is a pioneer in the burgeoning field of single-cell engineering and biology. Powered by innovative techniques he has developed for molecular profiling of single cells, his scientific discoveries range from the molecular underpinnings of cellular variability to the behavior of single cells across biology, including in diseases such as cancer.
Raj will deliver the 2023-24 Heilmeier Lecture at Penn Engineering during the spring 2024 semester.
This story originally appeared in Penn Engineering Today.
How does the placenta keep harmful substances away from developing babies while still providing proper nutrition?
(Photo: Getty Images)
The exact mechanisms remain unknown, which is why the University of Pennsylvania, Rutgers University, Tulane University, the University of North Carolina at Chapel Hill and the University of Rochester have joined together to launch a research center dedicated to solving this mystery and ensuring healthy pregnancies.
A $5 million grant from the National Institutes of Health (NIH) will help fund the Integrated Transporter Elucidation Center (InTEC), which will operate from the Rutgers Biomedical Health Sciences campus in Piscataway under the leadership of Lauren Aleksunes, a professor of pharmacology and toxicology at Rutgers’ Ernest Mario School of Pharmacy and resident scientist in the Environmental and Occupational Health Sciences Institute (EOHSI).
“Since my time working as a community pharmacist, I have found the lack of high-quality information about the safety of everyday products on the health of a pregnancy frustrating,” says Aleksunes. “People need to know whether the chemicals in their diet, personal care products and medications can impact their babies. Our goal at InTEC is to better understand how these chemicals travel in and out of the placenta and if they can reach the baby and influence their development.”
Aleksunes will study how transporter proteins carrying nutrients, dietary supplements, medications and toxic chemicals work during pregnancies. Some of the work will test how individual placenta cells respond to various stimuli in the laboratory. Others on the team will examine how environmental factors influence placental transporters during healthy and unhealthy or complicated pregnancies.
Key to this work will be Dan Huh, Associate Professor in Bioengineering in Penn Engineering, who will lead a team with an innovative approach to modeling the transfer of molecules across the human placenta.
As a pioneer of organ-on-a-chip technology, the Huh group will use a novel microengineered system in which maternal tissue engineered from a layer of primary human trophoblasts is grown adjacent to a three-dimensional network of perfusable fetal blood vessels to mimic the human placental barrier. This microphysiological system will be employed as an in vitro platform to simulate and quantitatively analyze the exchange of various substances between maternal and fetal circulation without the need for laboratory animals or placenta explants.
Ajay Thatte, Benjamin Nachod, Rohan Palanki, Kelsey Swingle, Alex Hamilton, and Michael Mitchell (Left to Right – Courtesy of the Mitchell Lab)
Autoimmune disorders are among the most prevalent chronic diseases across the globe, affecting approximately 5-7% of the world’s population. Emerging treatments for autoimmune disorders focus on “adoptive cell therapies,” or those using cells from a patient’s own body to achieve immunosuppression. These therapeutic cells are recognized by the patient’s body as ‘self,’ therefore limiting side effects, and are specifically engineered to localize the intended therapeutic effect.
In treating autoimmune diseases, current adoptive cell therapies have largely centered around the regulatory T cell (Treg), which is defined by the expression of the Forkhead box protein 3, orFoxp3. Although Tregs offer great potential, using them for therapeutic purposes remains a major challenge. In particular, current delivery methods result in inefficient engineering of T cells.
Tregs only compose approximately 5-10% of circulating peripheral blood mononuclear cells. Furthermore, Tregs lack more specific surface markers that differentiate them from other T cell populations. These hurdles make it difficult to harvest, purify and grow Tregs to therapeutically relevant numbers. Although there are additional tissue-resident Tregs in non-lymphoid organs such as in skeletal muscle and visceral adipose tissue, these Tregs are severely inaccessible and low in number.
“The major challenges associated with ex vivo (outside the body) cell engineering are efficiency, toxicity, and scale-up: our mRNA lipid nanoparticles (mRNA LNPs) allow us to overcome all of these issues,” says Mitchell. “Our work’s novelty comes from three major components: first, the use of mRNA, which allows for the generation of transient immunosuppressive cells; second, the use of LNPs, which allow for effective delivery of mRNA and efficient cell engineering; and last, the ex vivo engineering of primary human T cells for autoimmune diseases, offering the most direct pipeline for clinical translation of this therapy from bench to bedside.”
“To our knowledge, this is one of the first mRNA LNP platforms that has been used to engineer T cells for autoimmune therapies,” he continues. “Broadly, this platform can be used to engineer adoptive cell therapies for specific autoimmune diseases and can potentially be used to create therapeutic avenues for allergies, organ transplantation and beyond.”
Delivering the Foxp3 protein to T cells has been difficult because proteins do not readily cross the cell membrane. “The mRNA encodes for Foxp3 protein, which is a transcription factor that makes the T cells immunosuppressive rather than active,” explains first author Ajay Thatte, a doctoral student in Bioengineering and NSF Fellow in the Mitchell Lab. “These engineered T cells can suppress effector T cell function, which is important as T cell hyperactivity is a common phenotype in autoimmune diseases.”
NAM, founded in 1970, is an independent organization of professionals that advises the entire scientific community on critical health care issues. Each year, NAM chooses up to 10 new ELHM Scholars who are early-to-mid-career professionals from a wide range of health-related fields, including biomedical engineering, internal medicine, psychiatry, radiology and journalism to serve a three-year term.
“We are delighted that Dr. de la Fuente is receiving recognition from the National Academy of Medicine for his breakthrough contributions and exceptional leadership in the life sciences,” says Vijay Kumar, Nemirovsky Family Dean of Penn Engineering. “His pioneering work using computers to accelerate antibiotic discovery is extraordinary. We proudly celebrate his selection as part of this outstanding group of scholars.”
Congratulations to the members of the Penn Bioengineering community who were awarded 2023 Accelerating from Lab to Market Pre-Seed Grants from the University of Pennsylvania Office of the Vice Provost for Research (OVPR).
Andrew Tsourkas, Ph.D.
Three faculty affiliated with Bioengineering were included among the four winners. Andrew Tsourkas, Professor in Bioengineering and Co-Director of the Center for Targeted Therapeutics and Translational Nanomedicine (CT3N), was awarded for his project titled “Precise labeling of protein scaffolds with fluorescent dyes for use in biomedical applications.” Tsourkas’s team created protein scaffold that can better control the location and orientation of fluorescent dyes, commonly used for a variety of biomedical applications, such as labeling antibodies or fluorescence-guided surgery. The Tsourkas Lab specializes in “creating novel targeted imaging and therapeutic agents for the detection and/or treatment of diverse diseases.”
Also awarded were Penn Bioengineering Graduate Group members Mark Anthony Sellmeyer, Assistant Professor in Radiology in the Perelman School of Medicine, and Rahul M. Kohli, Associate Professor of Medicine in the Division of Infectious Diseases in the Perelman School of Medicine.
From the OVPR website:
“Penn makes significant commitments to academic research as one of its core missions, including investment in faculty research programs. In some disciplines, the path by which discovery makes an impact on society is through commercialization. Pre-seed grants are often the limiting step for new ideas to cross the ‘valley of death’ between federal research funding and commercial success. Accelerating from Lab to Market Pre-Seed Grant program aims to help to bridge this gap.”
Read the full list of winning projects and abstracts at the OVPR website.
Paul Ducheyne, Professor Emeritus in Bioengineering and Orthopaedic Surgery Research, has won the 2023 Hironobu Oonishi Memorial Award from the International Society for Ceramics in Medicine (ISCM). This award, the ISCM’s top honor, will only be awarded ten times in total, with previous honorees hailing from Japan and France and focusing on clinical research and life sciences. As the fifth honoree, Ducheyne is the first biomaterials researcher and engineer to win this distinguished prize.
Dr. Hironobu Oonishi was one of the founders of the International Society for Ceramics in Medicine and a leading hip surgeon. He was known for his discovery that irradiated polyethylene displayed greatly improved wear resistance in total joint replacements. In his memory, the ISCM and Kyocera created the Hironobu Oohnishi Memorial Award, with the goal to honor scientists who contributed to ISCM and greatly advanced the clinical use of bioceramics. Each year, the awardee is selected by a committee chaired by Dr. Hiroshi Oonishi, Dr. Hironobu Oonishi’s son. Once ten awardees have been selected, the award granting process will be closed.
Dr. Ducheyne accepted his award at the ISCM annual meeting in Solothurn, Switzerland in October 2023, where he delivered the Opening Ceremony lecture entitled “Bioceramics and Clinical Use – the struggle of memory against forgetting.”
Dr. Ducheyne has been a leading scientist in the field of biomaterial research for decades, with seminal contributions to biomaterials research, especially as it relates to orthopaedics. In bioceramics research, he clearly delineated the unusual properties of engineered bioactive ceramics. Not only was he at the vanguard of the development of these materials, he also generated a fundamental understanding of how these materials exhibit bone bioactive properties and promote skeletal healing. His group has also studied inorganic controlled release materials and has demonstrated the utility of sol-gel synthesized silica-based nanoporous materials for therapeutic use. These materials may well represent a next generation of agents for delivery of drugs, including antibiotics, analgesics, and osteogenic and anti-inflammatory molecules.
During his tenure at Penn, he directed the Center for Bioactive Materials and Tissue Engineering. He was also a Special Guest Professor at the KU Leuven, Belgium. He has founded several successful companies: XeroThera, a spin-out from Penn, that is developing advanced controlled delivery concepts for prophylaxis and treatment of surgical infections; Orthovita, a leading, independent biomaterials company in the world with more than 250 employees at the time of its acquisition by Stryker in June 2011; and Gentis, Inc., which focuses on breakthrough concepts for spinal disorders.
Congratulations to Dr. Ducheyne from everyone at Penn Bioengineering.
Michel Koo of the School of Dental Medicine and David Cormode of the Perelman School of Medicine and the School of Engineering and Applied Science led a team of researchers that uncovered a way to combine two FDA-approved treatments to treat tooth decay that taps into the blend’s bacteria-killing capabilities without disrupting the mouth’s microbiome. (Image: iStock / Alex Sholom)
The sting of a toothache or the discovery of a cavity is a universal dread. Dental caries, more commonly known as tooth decay, is an insidious adversary, taking a toll on millions of mouths worldwide. Caries can lead to pain, tooth loss, infection, and, in severe cases, even death.
While fluoride-based treatments have long been the gold standard in dentistry, this singular approach is now dated and has limited effect. Current treatments do not sufficiently control biofilm—the main culprit behind dental caries—and prevent enamel demineralization at the same time. This dual dilemma becomes particularly pronounced in high-risk populations where the onset of the disease can be both rapid and severe.
“Traditional treatments often come short in managing the complex biofilm environment in the mouth,” Koo, senior co-author on the study, says. “Our combined treatment not only amplifies the effectiveness of each agent but does so with a lower dosage, hinting at a potentially revolutionary method for caries prevention in high-risk individuals.”
David Cormode is an associate professor of radiology and bioengineering with appointments in Penn’s Perelman School of Medicine and School of Engineering and Applied Science.
Other authors are Yue Huang, Nil Kanatha Pandey, Shrey Shah, and Jessica C. Hsu of Penn’s Perelman School of Medicine; Yuan Liu, Aurea Simon-Soro, Zhi Ren, Zhenting Xiaang, Dongyeop Kim, Tatsuro Ito, Min Jun Oh, and Yong Li of Penn’s School of Dental Medicine; Paul. J Smeets, Sarah Boyer, Xingchen Zhao, and Derk Joester of Northwestern University; and Domenick T. Zero of Indiana University.
The work was supported by the National Institute of Health (grants R01-DE025848 and TL1TR001423 and awards S10OD026871 and R90DE031532) and the National Science Foundation (awards ECCS-2025633 and DMR-1720139).
